{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:22:52Z","timestamp":1792408972618,"version":"4.4.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PI20\/00744"],"award-info":[{"award-number":["PI20\/00744"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PI19\/00588"],"award-info":[{"award-number":["PI19\/00588"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PI19\/00815"],"award-info":[{"award-number":["PI19\/00815"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PI21\/01292"],"award-info":[{"award-number":["PI21\/01292"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PI21\/00251"],"award-info":[{"award-number":["PI21\/00251"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0005\/0001"],"award-info":[{"award-number":["RD21\/0005\/0001"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0005\/0016"],"award-info":[{"award-number":["RD21\/0005\/0016"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>In the EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) trial, empagliflozin reduced cardiorenal outcomes by 28% (hazard ratio 0.72; 95% confidence interval 0.64\u20130.82; P\u00a0&amp;lt;\u00a0.0001) in a diverse population of over 6000 chronic kidney disease (CKD) patients, of whom &amp;gt;50% were not diabetic. It expanded the spectrum of CKD that may benefit from sodium-glucose cotransporter 2 (SGLT2) inhibition to participants with urinary albumin: creatinine ratio &amp;lt;30\u00a0mg\/g and estimated glomerular filtration rate (eGFR) &amp;gt;20\u00a0mL\/min\/1.73 m2 or even lower (254 participants had an eGFR 15\u201320\u00a0mL\/min\/1.73 m2). EMPA-KIDNEY was stopped prematurely because of efficacy, thus limiting the ability to confirm benefit on the primary outcome in every pre-specified subgroup, especially in those with more slowly progressive CKD. However, data on chronic eGFR slopes were consistent with benefit at any eGFR or urinary albumin:creatinine ratio level potentially delaying kidney replacement therapy by 2\u201327 years, depending on baseline eGFR. The representation of diverse causes of CKD (&amp;gt;1600 participants with glomerular disease, &amp;gt;1400 with hypertensive kidney disease, &amp;gt;450 with tubulointerstitial disease and &amp;gt;600 with unknown cause) was higher than in prior SGLT2 inhibitor trials, although polycystic kidney disease was excluded. Around 15% (almost 1000) of participants were not on renin\u2013angiotensin system blockade. The clinical characteristics of the cohort differed from DAPA-CKD (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease), as did the frequency of individual components of the primary outcome in the placebo arm. Thus, rather than compare EMPA-KIDNEY with DAPA-CKD, the results of both trials should be seen as complementary to those of other SGLT2 inhibitor trials. Overall, EMPA-KIDNEY, a recent meta-analysis and post hoc analyses of participants with type 2 diabetes mellitus (T2DM) but no baseline CKD in other trials, indicates that SGLT2 inhibitor treatment will benefit an expanded CKD population with diverse baseline albuminuria or eGFR values, presence of T2DM or cause of CKD, as well as providing primary prevention of CKD in at least the T2DM setting.<\/jats:p>","DOI":"10.1093\/ckj\/sfad082","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T01:55:26Z","timestamp":1686966926000},"page":"1187-1198","source":"Crossref","is-referenced-by-count":122,"title":["EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors"],"prefix":"10.1093","volume":"16","author":[{"given":"Beatriz","family":"Fern\u00e1ndez-Fernandez","sequence":"first","affiliation":[{"name":"Department of Nephrology and Hypertension , IIS-Fundacion Jimenez Diaz UAM, Madrid , Spain"},{"name":"RICORS2040 , Madrid , Spain"},{"name":"Departamento de Medicina, Facultad de Medicina, Universidad Aut\u00f3noma de Madrid , Madrid , Spain"},{"name":"GEENDIAB, Sociedad Espa\u00f1ola de Nefrolog\u00eda , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Sarafidis","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Soler","sequence":"additional","affiliation":[{"name":"RICORS2040 , Madrid , Spain"},{"name":"GEENDIAB, Sociedad Espa\u00f1ola de Nefrolog\u00eda , Spain"},{"name":"Nephrology Department, Vall d'Hebron University Hospital , Vall d'Hebron Institue of Research, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension , IIS-Fundacion Jimenez Diaz UAM, Madrid , Spain"},{"name":"RICORS2040 , Madrid , Spain"},{"name":"Departamento de Medicina, Facultad de Medicina, Universidad Aut\u00f3noma de Madrid , Madrid , Spain"},{"name":"GEENDIAB, Sociedad Espa\u00f1ola de Nefrolog\u00eda , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"2023073100371126200_bib1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ckj\/sfz007","article-title":"Clarifying the concept of chronic kidney disease for non-nephrologists","volume":"12","author":"Perez-Gomez","year":"2019","journal-title":"Clin Kidney J"},{"key":"2023073100371126200_bib2","first-page":"1","article-title":"Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Disease","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2023073100371126200_bib3","first-page":"527","article-title":"Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association","volume-title":"Nephrol Dial Transplant","author":"Ortiz","year":"2023"},{"key":"2023073100371126200_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ckj\/sfab170","article-title":"RICORS2040: the need for collaborative research in chronic kidney disease","volume":"15","author":"Ortiz","year":"2021","journal-title":"Clin Kidney J"},{"key":"2023073100371126200_bib5","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet North Am Ed"},{"key":"2023073100371126200_bib6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"2023073100371126200_bib7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2023073100371126200_bib8","article-title":"Summary of product characteristics","author":"ANNEX I"},{"key":"2023073100371126200_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2023073100371126200_bib10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"2023073100371126200_bib11","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"2023073100371126200_bib12","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023073100371126200_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2023073100371126200_bib14","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2023073100371126200_bib15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00125-022-05694-6","article-title":"Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial","volume":"65","author":"Waijer","year":"2022","journal-title":"Diabetologia"},{"key":"2023073100371126200_bib16","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","volume":"35","author":"Wheeler","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2023073100371126200_bib17","first-page":"1317","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial","volume-title":"Nephrol Dial Transplant","author":"EMPA-KIDNEY Collaborative Group","year":"2022"},{"key":"2023073100371126200_bib18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"2023073100371126200_bib19","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.kint.2017.05.021","article-title":"Mucosal corticosteroid therapy of IgA nephropathy","volume":"92","author":"Floege","year":"2017","journal-title":"Kidney Int"},{"key":"2023073100371126200_bib20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"2023073100371126200_bib21","first-page":"1080","article-title":"The European Green Deal and nephrology: a call for action by the European Kidney Health Alliance (EKHA)","volume-title":"Nephrol Dial Transplant","author":"Vanholder","year":"2023"},{"key":"2023073100371126200_bib22","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and major renal outcomes in heart failure","volume":"385","author":"Packer","year":"2021","journal-title":"N Engl J Med"},{"key":"2023073100371126200_bib23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2023073100371126200_bib24","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate \u201cdip\u201d upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"key":"2023073100371126200_bib25","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.2337\/dc22-0382","article-title":"Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial","volume":"45","author":"Mosenzon","year":"2022","journal-title":"Diabetes Care"},{"key":"2023073100371126200_bib26","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2215\/CJN.14901219","article-title":"Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial","volume":"15","author":"Levin","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023073100371126200_bib27","article-title":"The aging kidney","author":"Rule"},{"key":"2023073100371126200_bib28","first-page":"1891","article-title":"Sex differences in age-related loss of kidney function","volume-title":"J Am Soc Nephrol","author":"Melsom","year":"2022"},{"key":"2023073100371126200_bib29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.kint.2016.09.052","article-title":"Residual renal function: a paradigm shift","volume":"91","author":"Lowenstein","year":"2017","journal-title":"Kidney Int"},{"key":"2023073100371126200_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-139-2-200307150-00010","article-title":"Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study","volume":"139","author":"Li","year":"2003","journal-title":"Ann Intern Med"},{"key":"2023073100371126200_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2023073100371126200_bib32","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/ckj\/sfac029","article-title":"Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction","volume":"15","author":"Afsar","year":"2022","journal-title":"Clin Kidney J"},{"key":"2023073100371126200_bib33","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/nep.13941","article-title":"Sodium-glucose cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: review of the current evidence","volume":"26","author":"Kanbay","year":"2021","journal-title":"Nephrology (Carlton)"},{"key":"2023073100371126200_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023073100371126200_bib35","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023073100371126200_bib36","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2023073100371126200_bib37","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","article-title":"The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia","volume":"62","author":"Himmelfarb","year":"2002","journal-title":"Kidney Int"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad082\/50696644\/sfad082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/8\/1187\/50925935\/sfad082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/8\/1187\/50925935\/sfad082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:37:37Z","timestamp":1690763857000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/8\/1187\/7199787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,6,16]]},"published-print":{"date-parts":[[2023,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad082","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,6,16]]}}}